Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 15;131(6):e35795.
doi: 10.1002/cncr.35795.

Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States

Nikhil T Sebastian  1 , Dattatraya Patil  2 , Pretesh R Patel  1 , Ashesh B Jani  1 , Bruce W Hershatter  1 , Vishal R Dhere  1 , Karen D Godette  1 , C Adam Lorentz  2 , Aaron D Weiss  2 , Shreyas S Joshi  2 , Martin G Sanda  2 , Sagar A Patel  1   2
Affiliations

Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States

Nikhil T Sebastian et al. Cancer. .

Abstract

Background: Radical prostatectomy (RP) and radiotherapy (RT) are standard-of-care treatments for localized prostate cancer. The authors studied the utilization and total health care and patient-incurred costs of RP and RT in the United States using the Merative MarketScan Medicare (Medicare Supplemental and Coordination of Benefits [MDCR]) and Commercial (Commercial Claims and Encounters [CCAE]) databases.

Methods: Men were identified who had nonmetastatic prostate cancer treated with RP, external-beam RT (EBRT), brachytherapy (BT), EBRT combined with BT (EBRT + BT), stereotactic body RT (SBRT), or proton-beam therapy (PBT) between 2009 and 2022. Year-to-year treatment utilization was compared using the Kendall Tau-b test. Mean total health care and patient out-of-pocket costs within 12 months of treatment were compared using the Kruskal-Wallis test.

Results: In the MDCR database, 44,937 patients were identified who received treatment with RP (n = 12,879), EBRT (n = 26,193), BT (n = 926), EBRT + BT (n = 4706), PBT (n = 57), or SBRT (n = 176). Between 2009 and 2021, EBRT use increased from 52.5% to 62.2% (p for trend < .001), SBRT increased from 0.4% to 0.5% (p < .001), BT decreased from 3.1% to 1.0% (p < .001), and EBRT + BT decreased from 14.8% to 6.8% (p < 0.001); whereas use remained similar for RP (from 29.1% to 29.4%; p = .82) and PBT (from 0.1% to 0.1%; p = .93). In the CCAE database, 75,626 patients were identified who received treatment with RP (n = 50,278), EBRT (n = 16,985), BT (n = 1243), EBRT + BT (n = 6811), PBT (n = 92), or SBRT (n = 217). EBRT use increased from 20.0% to 24.9% (p < .001), SBRT increased from 0.1% to 0.8% (p < .001), BT decreased from 2.5% to 0.7% (p < .001), and EBRT + BT decreased from 10.6% to 7.4% (p < .001); whereas use remained similar for RP (from 66.8% to 66.1%; p for trend = .82), and PBT (from 0.1% to 0.1%; p for trend = .76). In the MDCR and CCAE databases, PBT had the highest total cost, whereas BT had the lowest.

Conclusions: Between 2009 and 2021, there was increasing use of EBRT and SBRT, whereas use of RP remained stable. Although BT was the least costly, its utilization as monotherapy and combined with EBRT declined.

Keywords: brachytherapy; cost; external‐beam radiation therapy; prostate cancer; prostatectomy; proton therapy; stereotactic body radiation therapy.

PubMed Disclaimer

References

REFERENCES

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49. doi:10.3322/caac.21820
    1. Kishan AU, Cook RR, Ciezki JP, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer. JAMA. 2018;319(9):896‐905. doi:10.1001/jama.2018.0587
    1. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547‐1558. doi:10.1056/nejmoa2214122
    1. Michalski JM, Winter KA, Prestidge BR, et al. Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate‐risk prostate cancer: NRG Oncology RTOG 0232 randomized clinical trial. J Clin Oncol. 2023;41(24):4035‐4044. doi:10.1200/jco.22.01856
    1. Oh J, Tyldesley S, Pai H, et al. An updated analysis of the survival endpoints of ASCENDE‐RT. Int J Radiat Oncol Biol Phys. 2023;115(5):1061‐1070. doi:10.1016/j.ijrobp.2022.11.005